Stock data
| Market cap. | €139.7m |
| Last close | €4.09 |
| High / Low (52 weeks) | €5.0 / €1.8 |
| Stock market listing | SP |
| Forecast net cash (€m) | 0.1 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 18.7 | 69.0 | 40.9 |
| Relative * | 19.1 | 71.6 | 53.5 |
* % Relative to local index
Other companies in sector Show
Company news
Investment summary
The next year is shaping up to be transformative for Oryzon with two data readouts from Phase IIa trials with ORY-2001 in Alzheimer’s disease (AD) and multiple sclerosis (MS). In addition, an innovative design basket trial with ORY-2001 in several neuropsychiatric disorders may also deliver first results next year. Oryzon is resuming the development of ORY-1001 in acute myeloid leukaemia (AML) and small-cell lung cancer (SCLC). While Roche’s departure was a setback in 2017, the stars started to align again after the Biogen Abeta antibody data provided a much-needed boost for AD research industry and indirectly for Oryzon’s ORY-2001. Furthermore, a fundamental study published in Cell described the potential of LSD1 inhibition in immunooncology setting adding a new dimension to ORY-1001’s potential. We value Oryzon at €328m or €9.6/share (vs €9.4/share).
Last updated on 18/07/2018
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 5.0 | (3.7) | (4.7) | (17.02) | N/A | N/A |
| 2017A | 4.3 | (3.5) | (4.6) | (14.29) | N/A | N/A |
| 2018E | 7.0 | (4.7) | (5.6) | (16.34) | N/A | N/A |
| 2019E | 6.3 | (6.4) | (7.3) | (21.26) | N/A | N/A |
Last updated on 18/07/2018
Latest research
Awaiting for eventful 2019
Outlook | Pharmaceutical & healthcare | 18/07/2018
Phase IIa trial in Alzheimer's disease initiated
Update | Pharmaceutical & healthcare | 22/05/2018
Multiple data readouts in 2019 within cash reach
Update | Pharmaceutical & healthcare | 08/03/2018
New data support holistic effects of ORY-2001
Update | Pharmaceutical & healthcare | 14/12/2017
ORY-1001 rights back to Oryzon
Update | Pharmaceutical & healthcare | 22/08/2017
Roche returns rights on ORY-1001
Flash note | Pharmaceutical & healthcare | 21/07/2017
ORY-2001 and ORY-3001 next in focus
Update | Pharmaceutical & healthcare | 22/05/2017
Maturing epigenetics portfolio
Outlook | Pharmaceutical & healthcare | 02/05/2017
New data further back MS indication
Update | Pharmaceutical & healthcare | 13/03/2017
Expanding clinical R&D pipeline
Update | Pharmaceutical & healthcare | 09/12/2016
First look at ORY-1001 Phase I/IIa data
Update | Pharmaceutical & healthcare | 16/11/2016
Fresh preclinical ORY-2001 data, ORY-1001 next
Update | Pharmaceutical & healthcare | 03/11/2016
Latest video
Industry outlook
Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.
Last updated on 29/06/2018
Key management
| Carlos Buesa, CEO |
Company address
| Sant Ferran 74 Cornellà de Llobregat Barcelona 08940 United Kingdom View website |